Clinical Trials Logo

Filter by:
NCT ID: NCT03805100 Not yet recruiting - Clinical trials for Macular Degeneration

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

XPLORE
Start date: March 2019
Phase: Phase 3
Study type: Interventional

The objectives of this study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).

NCT ID: NCT03804411 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Prognostic Predictors of Response to Hypoglycemic Therapy

Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

This is a randomized controlled trial aimed to determine highly specific personified predictors of response to the therapy by different groups of hypoglycemic drugs (SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas) in patients with type 2 diabetes mellitus, develop an algorithm of personalized therapy based on them, design an organizational and methodological model for prevention of the cardiovascular complications, and create an automated decision-making system for therapy selection to reduce the incidence of cardiovascular events and related adverse outcomes compared to the traditional approach. This is an interventional, randomized controlled trial, open-label study.

NCT ID: NCT03800134 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Start date: December 6, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathological response.

NCT ID: NCT03797118 Recruiting - Clinical trials for Coronary Artery Disease

One-Dimensional Mathematical Model-Based Automated Assessment of Fractional Flow Reserve

Start date: April 5, 2017
Phase: N/A
Study type: Interventional

This study evaluates the diagnostic efficiency of an automated method of noninvasive assessment of the fractional reserve of coronary blood flow. Fractional flow reserve is estimated with a one-dimensional mathematical model constructed by means of an automated algorithm. Noninvasive method values are thereafter compared with invasive method values.

NCT ID: NCT03796858 Not yet recruiting - Clinical trials for Arthritis, Psoriatic

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy

COSMOS
Start date: February 4, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the reduction in signs and symptoms of joint disease.

NCT ID: NCT03790917 Completed - Atrial Fibrillation Clinical Trials

Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY

ANTEY
Start date: September 5, 2017
Phase:
Study type: Observational

A prospective non-interventional single-center study aimed to evaluate actual adherence of AF patients using the 8-item Morisky Medication Adherence Scale. Primary Study Objective(s) Primary study objective The aim of the present study is to assess adherence to therapy and factors associated with adherence in patients with CV disease complicated by non-valvular atrial fibrillation requiring OAC treatment within the outpatient registry PROFILE (prospective, observational study). 1. Data collection in patients with non-valvular atrial fibrillation requiring OAC treatment included in the registry 2. Evaluation of actual patient adherence to OACs Secondary Study Objective(s) 1. Evaluation of potential patient adherence to OACs 2. Determination of the most significant factors associated with adherence to OACs in patients with non-valvular AF 3. Validation of new original 5-item Questionnaire 4. Evaluation of doctor's adherence to OAC prescription according to Guidelines (ESC). Management of atrial fibrillation,2016)

NCT ID: NCT03789695 Recruiting - Atrial Fibrillation Clinical Trials

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2D and CKD

RE-ELECT
Start date: November 14, 2018
Phase: Phase 4
Study type: Interventional

Kidney function in patients with atrial fibrillation (AF) is tending to decline over a time which is clearly demonstrated in clinical studies. Taking into account that renal impairment is a risk factor for stroke and its progression is associated with unfavorable prognosis it's clear that preserving kidney function should be considered as a one of priorities when choosing treatment strategies which is especially important in patients with existing chronic kidney disease or in patients who are under risk of its development. This is especially relevant for the patients with Diabetes mellitus and with Chronic kidney disease who can be considered as a group of risk of rapid progression of kidney function decline.

NCT ID: NCT03789539 Active, not recruiting - Safety Issues Clinical Trials

Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu

Start date: June 2, 2018
Phase: Phase 1
Study type: Interventional

This is a single-site, randomized, double-blind, placebo-controlled study of Uniflu in fifty four (54) volunteers 18-60 years of age with a dose escalation. All subjects will receive an intramuscular (IM) injection twice,with a 21 days interval between treatments.

NCT ID: NCT03789019 Completed - Clinical trials for Metastatic Breast Cancer

BP-C1 Monotherapy in Patients With Metastatic Breast Cancer: Estimation of Optimal Duration of Treatment

Start date: February 22, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish an optimal treatment duration and tolerable cumulative dose for BP-C1 in the treatment of metastatic breast cancer patients who had previously undergone at least three lines of chemotherapy.

NCT ID: NCT03786965 Recruiting - Clinical trials for Ischemic Heart Disease

Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.

MPO-CSP
Start date: December 20, 2018
Phase: N/A
Study type: Interventional

The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.